Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Amortizatization of Intangibles (2016 - 2025)

Integra Lifesciences Holdings' Amortizatization of Intangibles history spans 13 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 27.5% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $5.6 million, changed 0.21%, while the annual FY2025 figure was $5.6 million, 0.21% changed from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $1.0 million at Integra Lifesciences Holdings, down from $1.3 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.8 million in Q3 2021 and bottomed at $807000.0 in Q2 2021.
  • The 5-year median for Amortizatization of Intangibles is $1.4 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Amortizatization of Intangibles crashed 73.3% in 2021 before it surged 106.69% in 2022.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $1.7 million in 2021, then dropped by 1.1% to $1.7 million in 2022, then fell by 15.85% to $1.4 million in 2023, then fell by 2.3% to $1.4 million in 2024, then fell by 27.5% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Amortizatization of Intangibles are $1.0 million (Q4 2025), $1.3 million (Q3 2025), and $1.9 million (Q2 2025).